STEM CELLS
& EXOSOMES
THE SCIENCE
OF REPAIR
An evidence-first look at regenerative medicine, and how it may support tissue repair as your intrinsic capacity changes with age.
WHAT ARE STEM CELLS?
Stem cells are your body’s built-in repair system. With age, they decline in number and work less effectively. Scientists call this stem-cell exhaustion, one of the recognized hallmarks of aging.
Unlike most cells, stem cells can renew themselves and, under the right conditions, become specialized cells. Different populations maintain blood, skin, muscle and bone. They also signal to nearby cells by releasing growth factors, cytokines and extracellular vesicles. Exosomes are one type of these vesicles, studied for their role in cell-to-cell communication.
With age, inflammation, DNA damage, mitochondrial dysfunction and cellular senescence make stem cells less responsive. The result can be slower, less complete tissue repair, one contributor to the gradual decline in intrinsic capacity that the CogSpan™ System is designed to track.
Researchers are studying stem cells, umbilical-cord-derived products and other regenerative biologics for many conditions, and most proposed uses remain investigational. A product labeled umbilical-cord-derived is not necessarily a stem-cell product; its contents depend on how it was collected, processed and manufactured. Most of these products are not FDA-approved and have not been proven safe or effective for many of the conditions they are marketed for.
WHAT DOES THE RESEARCH SHOW?
COGNITIVE HEALTH
Alzheimer’s, Parkinson’s and age-related cognitive decline share common drivers: neuroinflammation, oxidative stress and disrupted cell signaling. Early research suggests MSC-derived exosomes may cross the blood-brain barrier and act on these pathways. International clinical trials are underway; no stem cell or exosome therapy is approved to treat these conditions.
JOINT PAIN & OSTEOARTHRITIS
Osteoarthritis affects tens of millions of people and has no cure. In clinical studies, MSC injections into the joint have been associated with less pain and better function; a small pilot study of 33 Navy SEAL veterans reported significant improvement at six months. A 2025 meta-analysis in Frontiers in Pharmacology pointed to anti-inflammatory and cartilage-protective effects.
NEUROPATHY
Peripheral neuropathy from diabetes, chemotherapy or injury causes pain, weakness and numbness. MSC-derived exosomes carry proteins and RNA that may support nerve repair. A 2024 review in Frontiers in Cellular Neuroscience described neuroprotective effects in spinal cord, optic nerve and peripheral nerve research.
HAIR LOSS
MSC-derived exosomes are being studied for pattern hair loss, chemotherapy-related hair loss and autoimmune hair loss. A 2025 systematic review of 11 clinical studies reported improved hair regrowth, likely through reduced follicle inflammation and activation of the hair-growth cycle. Our physician-designed protocol combines exosomes, growth factors and cytokines. Individual results vary.
AUTOIMMUNE & NEUROMUSCULAR
MSCs are among the most studied regenerative therapies for calming inflammation and rebalancing the immune system. Early studies in lupus and in ALS show encouraging safety and possible quality-of-life benefits. These findings are preliminary, and ALS has no cure. A physician evaluation determines whether you are a candidate.
FERTILITY & OVARIAN HEALTH
For diminished ovarian reserve, premature ovarian insufficiency or chemotherapy-related fertility loss, MSC-derived exosomes are an active area of research. A 2024 systematic review found more follicles and better hormone profiles in preclinical models, and a 2024 study in the American Journal of Obstetrics and Gynecology suggested a protective effect on ovarian function during chemotherapy.
INFLAMMATION & SURGICAL RECOVERY
Inflammation is the body’s first response to injury, including surgery. When it persists, it can slow healing and increase scarring. In laboratory studies, MSC-derived exosomes shift immune cells called macrophages from a pro-inflammatory (M1) state toward a repair-oriented (M2) state.
A 2026 meta-analysis in Aesthetic Surgery Journal found faster wound healing, better blood-vessel formation and stronger tissue regeneration, mostly in preclinical models. In a 2026 randomized split-scar study of surgical incisions, the exosome-treated half showed greater improvement in pigmentation, pliability and thickness, confirmed at one year. In a randomized split-face trial of laser resurfacing, exosomes applied after treatment were associated with less redness and shorter recovery.
Research on exosomes before surgery is still early and largely preclinical. A physician evaluation determines whether this approach is appropriate around your procedure.
All protocols are physician-supervised and patient-specific. A physician evaluation is required prior to initiation. Individual results vary. Stem cell and exosome therapies are investigational and are not FDA-approved for the uses described on this page. These services are offered in compliance with California law and applicable federal regulations. All allogeneic cell products used in this practice are handled in accordance with FDA 21 CFR Part 1271 and California Health & Safety Code provisions for human tissue.